BASF starts up production plant for specialty amines in Ludwigshafen
Global leadership position in specialty amines strengthened.
BASF in Ludwigshafen has started up a world-scale plant for the production of specialty amines. The multi-product plant can manufacture approximately 12,000 metric tons per year of a product range of about 15 amines for different applications. Owing to its high flexibility, the plant can also be used for the production of new specialty amines. The major applications are currently in the construction, automotive, crop protection and pharmaceutical industries. With the new facility, BASF expands its global production network for amines with plants in Ludwigshafen and Schwarzheide in Germany; Antwerp, Belgium; Geismar, North America; and Nanjing, China.
“With the new plant, we are responding to our customers’ growing demand for specialty amines, particularly in Europe,” said Dr Stefan Blank, President, BASF Intermediates division. “We have decades of experience in developing and manufacturing amines and with the current expansion we are extending our global leadership in these versatile intermediates.”
“The special plant structure allows us to react flexibly to changes in the need for the various products. In addition, we can also produce commercial quantities of products from our innovation pipeline here,” said Dr Christoph Wegner, Senior Vice President, heading the regional business unit Amines Europe within BASF’s Intermediates division, and adds: “Being integrated into the BASF Verbund at the Ludwigshafen site also allows us to offer our customers, apart from research, the scale-up services through a pilot plant, all the way to the new multi-product plant.”
With about 200 different amines, BASF has the world’s most diverse portfolio of these chemical intermediates. In addition to alkylamines, alkanolamines and alkoxyalkylamines, the company also offers heterocyclic and aromatic amines as well as specialty amines. The range is completed by an expanding portfolio of chiral amines with high optical and chemical purity. The versatile products have proven their effectiveness above all in the manufacture of crop protection products and pharmaceuticals, as well as in cosmetics, detergents and process chemicals. They are also needed to produce coatings, special plastics, composites and special fibers.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.